Dimethyl fumarate alleviate hepatic ischemia–reperfusion injury through suppressing cGAS-STING signaling

Abstract

Hepatic ischemia–reperfusion (I/R) injury frequently occurs during the perioperative phase of liver surgery. Inappropriate activation of STING signaling can trigger excessive inflammation response to aggravate hepatic I/R injury. Dimethyl fumarate (DMF) is an FDA-approved immunomodulatory drug used to treat multiple sclerosis and psoriasis due to its notable anti-inflammation properties. However, the mechanism and targets of DMF in immunomodulation remain unclear. Here, we found that DMF suppresses cGAS-STING activation induced by HSV-1, hering testis DNA, and mitochondrial DNA in a variety of cells. DMF significantly reduces hepatic I/R injury and inhibits cGAS-STING pathway activation in mice. The alleviating effect of DMF on hepatic I/R injury was negligible in STING-knockout mice. Mechanistically, DMF directly inhibits STING activation via an autophagy-independent pathway, and the immunocoprecipitation experiment showed that DMF inhibited STING recruitment of downstream TBK1 and IRF3. Our study found that DMF protects liver I/R injury by inhibiting the STING pathway and may be a potential target of this disease.

Keywords

cGAS-STING / Dimethyl fumarate / Hepatic ischemia.reperfusion injury / Innate immunity

References

[1] Dickson I. Improving hepatic ischaemia-reperfusion injury outcomes. Nat Rev Gastroenterol Hepatol. 2019; 16(10): 583.

[2] Hirao H, Nakamura K, Kupiec-Weglinski JW. Liver ischaemia-reperfusion injury: a new understanding of the role of innate immunity. Nat Rev Gastroenterol Hepatol. 2022; 19(4): 239-256.

[3] Zhang J, Pan W, Zhang Y, et al. Comprehensive overview of Nrf2-related epigenetic regulations involved in ischemia-reperfusion injury. Theranostics. 2022; 12(15): 6626-6645.

[4] Zhong C, Yang J, Zhang Y, et al. TRPM2 mediates hepatic ischemia-reperfusion injury via Ca²⁺-induced mitochondrial lipid peroxidation through increasing ALOX12 expression. Research (Wash D C). 2023; 6: 0159.

[5] Wu XY, Chen YJ, Liu CA, et al. STING induces liver ischemia-reperfusion injury by promoting calcium-dependent caspase 1-GSDMD processing in macrophages. Oxid Med Cell Longev. 2022; 2022: 8123157.

[6] Shen A, Zheng D, Luo Y, et al. MicroRNA-24-3p alleviates hepatic ischemia and reperfusion injury in mice through the repression of STING signaling. Biochem Biophys Res Commun. 2020; 522(1): 47-52.

[7] Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021; 21(9): 548-569.

[8] Domizio JD, Gulen MF, Saidoune F, et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature. 2022; 603(7899): 145-151.

[9] Qin Y, Qiu D, Zhang Q. HNF1A regulates the crosstalk between innate immune responses and MAFLD by mediating autophagic degradation of TBK1. Autophagy. 2023; 19(3): 1026-1027.

[10] He J, Du C, Peng X, et al. Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis. Genes Dis. 2022; 10(4): 1596-1612.

[11] Li K, Gong Y, Qiu D, et al. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the anti-tumor efficacy of PD-1 antibody in HCC. J Immunother Cancer. 2022; 10(8): e004006.

[12] Liu K, Qiu D, Liang X, et al. Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy. Autophagy. 2022; 18(4): 860-876.

[13] Xiong Y, Chen J, Liang W, et al. Blockade of the mitochondrial DNA release ameliorates hepatic ischemia-reperfusion injury through avoiding the activation of cGAS-STING pathway. J Transl Med. 2024; 22(1): 796.

[14] Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005; 11(1): 43-48.

[15] Adam J, Hatipoglu E, O’Flaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011; 20(4): 524-537.

[16] Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018; 360(6387): 449-453.

[17] Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, et al. Succination inactivates gasdermin D and blocks pyroptosis. Science. 2020; 369(6511): 1633-1637.

[18] Zaro BW, Vinogradova EV, Lazar DC, et al. Dimethyl fumarate disrupts human innate immune signaling by targeting the IRAK4-MyD88 complex. J Immunol. 2019; 202(9): 2737-2746.

[19] Ryan TAJ, Hooftman A, Rehill AM, et al. Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress tissue factor in macrophages via inhibition of type I interferon. Nat Commun. 2023; 14(1): 3513.

[20] Alwithenani A, Taha Z, Thomson M, et al. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications. Front Immunol. 2023; 14: 1332929.

[21] Selman M, Ou P, Rousso C, et al. Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition. Sci Transl Med. 2018; 10(425): eaao1613.

[22] Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013; 339(6121): 786-791.

[23] Bryant JD, Lei Y, VanPortfliet JJ, et al. Assessing mitochondrial DNA release into the cytosol and subsequent activation of innate immune-related pathways in mammalian cells. Curr Protoc. 2022; 2(2): e372.

[24] Lee YS, Gupta DP, Park SH, et al. Anti-inflammatory effects of dimethyl fumarate in microglia via an autophagy dependent pathway. Front Pharmacol. 2021; 12: 612981.

[25] Kaluzki I, Hailemariam-Jahn T, Doll M, et al. Dimethylfumarate inhibits colorectal carcinoma cell proliferation: evidence for cell cycle arrest, apoptosis and autophagy. Cells. 2019; 8(11): 1329.

[26] Chen M, Meng Q, Qin Y, et al. TRIM14 inhibits cGAS degradation mediated by selective autophagy receptor p62 to promote innate immune responses. Molecular Cell. 2016; 64(1): 105-119.

[27] Kastrati I, Siklos MI, Calderon-Gierszal EL, et al. Dimethyl fumarate inhibits the nuclear factor κB pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 2016; 291(7): 3639-3647.

[28] Schmitt A, Xu W, Bucher P, et al. Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL. Blood. 2021; 138(10): 871-884.

[29] Zhu J, Wang Q, Li C, et al. Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate. Free Radic Biol Med. 2019; 134: 9-22.

[30] Ryan DG, Knatko EV, Casey AM, et al. Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response. iScience. 2022; 25(2): 103827.

[31] Zhang L, Jiang C, Zhong Y, et al. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 2023; 25(8): 1208-1222.

[32] Zhou S, Jin J, Bai T, et al. Potential drugs which activate nuclear factor E2-related factor 2 signaling to prevent diabetic cardiovascular complications: a focus on fumaric acid esters. Life Sci. 2015; 134: 56-62.

[33] Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011; 134(Pt 3): 678-692.

[34] Li TT, Luo YH, Yang H, et al. FBXW5 aggravates hepatic ischemia/reperfusion injury via promoting phosphorylation of ASK1 in a TRAF6-dependent manner. Int Immunopharmacol. 2021; 99: 107928.

[35] Huang Y, Liang W, Li K, et al. Sorafenib suppresses the activation of type I interferon pathway induced by RLR-MAVS and cGAS-STING signaling. Biochem Biophys Res Commun. 2022; 623: 181-188.

[36] Alderson NL, Wang Y, Blatnik M, et al. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys. 2006; 450(1): 1-8.

[37] Takasu C, Vaziri ND, Li S, et al. Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury. World J Gastroenterol. 2017; 23(25): 4508-4516.

[38] Liu Q, Wu Y, Qin Y, et al. Broad and diverse mechanisms used by deubiquitinase family members in regulating the type I interferon signaling pathway during antiviral responses. Sci Adv. 2018; 4(5): eaar2824.

[39] Lai X, Gong J, Wang W, et al. Acetyl-3-aminoethyl salicylate ameliorates hepatic ischemia/reperfusion injury and liver graft survival through a high-mobility group Box 1/Toll-like receptor 4-dependent mechanism. Liver Transpl. 2019; 25(8): 1220-1232.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.